- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
- Interventions
- Lepodisiran Sodium, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 222
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 171 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 49
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
- Interventions
- Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo
- Combination Product · Drug · Other
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 45
- States / cities
- Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Interventions
- Pelacarsen, Placebo, Inclisiran
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Sun City West, Arizona • Beverly Hills, California + 31 more
- Conditions
- Lipoprotein Disorder
- Interventions
- Kylo-11 or matched placebo
- Drug
- Lead sponsor
- Kylonova (Xiamen) Biopharma co., LTD.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Diego, California • Santa Maria, California + 13 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®
- Drug · Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Artery Calcification
- Interventions
- AI-Detected CAC Notification and Care Facilitation
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 120,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Pleasanton, California • Stanford, California + 3 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 20 more
- Conditions
- Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD)
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 45,456 participants
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Plainsboro, New Jersey
- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
- Interventions
- bempedoic acid, placebo
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 779 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Clearwater, Florida • Georgetown, Texas
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Pelacarsen (TQJ230)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 65 more
- Conditions
- Hypertension, Hyperlipidemias
- Interventions
- Penn Med Healthy Heart Program
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 1,980 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Obicetrapib, Placebo
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 199
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 161 more
- Conditions
- Cardiovascular Disease
- Interventions
- AZD0780, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 357
- States / cities
- Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 284 more
- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
- Interventions
- bempedoic acid
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio
- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
- Interventions
- bempedoic acid, placebo
- Drug · Other
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 52
- States / cities
- Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
- Conditions
- Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
- Interventions
- TQJ230, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more
- Conditions
- ASCVD, Elevated Cholesterol
- Interventions
- Inclisiran Sodium, Placebo
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 145
- States / cities
- Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Coronary Artery Calcium Scan, Carotid Artery Ultrasound, Lipoprotein(a) Measurement, Vascular Function Testing
- Diagnostic Test
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
- Interventions
- ETC-1002, Placebo
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
- Conditions
- Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
- Interventions
- Clazakizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 30
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Glendora, California + 24 more
- Conditions
- Lipoprotein Disorder
- Interventions
- LY3473329, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Dorchester, Massachusetts • Lima, Ohio
- Conditions
- Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
- Interventions
- ABP-745 Dose A, Placebo, ABP-745 Dose B, ABP-745 Dose C
- Drug
- Lead sponsor
- Atom Therapeutics Co., Ltd
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • San Diego, California • Torrance, California + 1 more
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Hypertension, Diabetes, Dyslipidemia, Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (Stage 3)
- Interventions
- Low-dose Colchicine at 0.5mg daily, Usual Care
- Drug · Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 204
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more